Nanogen announces diabetes research collaboration

May 15, 2006 – Nanogen Inc., a developer of advanced diagnostic products, announced a collaboration agreement with Finnish genomics company Oy Jurilab Ltd. The collaboration is designed to identify and validate new prognostic markers for type II diabetes, one of the leading causes of death in the United States.

Jurilab has access to genetic screening of an isolated population in East Finland, which the company says is derived from one of the most genetically homogeneous populations available.

Through the agreement, Nanogen will gain access to markers identified by Jurilab in genome-wide screens. Certain markers seem to be associated with predisposition to diabetes; others appear to protect against developing the disease. Both Jurilab and Nanogen say they plan to validate the diabetes associations of these markers in populations outside Finland.

POST A COMMENT

Easily post a comment below using your Linkedin, Twitter, Google or Facebook account. Comments won't automatically be posted to your social media accounts unless you select to share.